Kathryn R. Wagner, M.D., Ph.D. is the Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine. She treats patients with muscular dystrophies in a multidisciplinary clinic, addressing the multiple medical and social issues affecting these individuals and families. Dr. Wagner conducts clinical trials in muscular dystrophy including the first clinical trial of nonsense suppression in Duchenne and the first clinical trial of myostatin inhibition in adult muscular dystrophy. Prof. Wagner’s laboratory focuses on developing methods to promote muscle regeneration. A major emphasis of her laboratory has been on modulating myostatin, an endogenous regulator of muscle. Prof. Wagner’s laboratory has shown that inhibition of myostatin stimulates muscle stem cells, improving muscle regeneration while reducing fibrosis in animal models of muscular dystrophy. Current efforts include collaborations with industry to combine stem cell and pharmacological therapies for enhanced regeneration. She is a scientific advisor to the FSH Society and Parent Project Muscular Dystrophy and a member of the TREAT-NMD Advisory Committee for Therapeutics. Dr. Wagner is an elected member of the American Society of Clinical Investigation.